Viral Infections in Leukemia and Bone Marrow Transplant Patients

References

• Saral R., Bums W. H., Laskin O. L., et al. Acy-clovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone marrow transplant recipients. N. Engl. J. Med. 1981; 305: 63
   PubMed Web of Science ®Google Scholar
• Saral R., Ambinder R. F., Bums W. H., et al. Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients: a randomized, double-blind placebo controlled study. Ann. Intern. Med. 1983; 99: 773
   PubMed Web of Science ®Google Scholar
• Wingard J. R. Infectious and Noninfectious Systemic Consequences. Oral Complications of Cancer Therapies: Diagnosis, Prevention, and Treatment. NCI Monogr. 1990; 9: 21–26
   PubMedGoogle Scholar
• Wade J. C., Newton B., Flournoy N., Meyers I. D. Oral acyclovir prophylaxis of herpes simplex virus infection after marrow transplant. Ann. Intern. Med. 1984; 100: 823
   PubMed Web of Science ®Google Scholar
• Shepp D. H., Newton B. A., Dandliker P. S., et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. Ann. Intern. Med. 1985; 102: 783
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Wade J. C., Mitchell C. D., et al. Multicenter collaborative trial of intravenous acyclovir for the treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am. J. Med. 1982; 73A: 229
   Web of Science ®Google Scholar
• Mitchell C. D., Gentry S. R., Boen J. R., et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981; 2: 1389
   PubMedGoogle Scholar
• Wade J. C., Newton B., McLaren C., et al. Treatment of mucocutaneous herpes simplex virus infection after marrow transplantation with intravenous acyclovir: a double-blind trial. Ann. Intern. Med. 1982; 96: 265
   PubMed Web of Science ®Google Scholar
• Selby P. J., Jameson B., Watson J. G., et al. Parenteral acyclovir therapy for herpes virus infections in man. Lancet 1980; 2: 1267
   Web of Science ®Google Scholar
• Wade J. C., McLaren C., Meyers J. D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J. Infect. Dis. 1983; 148: 1077–1082
   PubMed Web of Science ®Google Scholar
• Erlich K. S., Mills J., Chatis P., et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1989; 320: 293–296
   PubMed Web of Science ®Google Scholar
• Wingard J. R., Piantadosi S., Bums W. H., et al. Cytomegalovirus Infections in Patients Treated by Intensive Cytoreductive Therapy with Marrow Transplant. Rev. Infect. Dis. 1990; 12(Suppl. 7)S805–S810
   PubMedGoogle Scholar
• Winston D. J., Ho W. G., Champlin R. E. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev. Infect. Dis. 1990; 12(Suppl. 7)S776–S792
   PubMedGoogle Scholar
• Meyers I. D., Floumoy N., Thomas E. D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 1986; 153: 478–488
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Thomas E. D. Non-bacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev. Infect. Dis. 1982; 4: 1119–1132
   PubMedGoogle Scholar
• Paulin T., Ringden O., Lönnqvist B., Wahren B., Nilsson B. The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection: analysis of risk factors. Scand. J. Infect. Dis. 1986; 18: 199–209
   PubMed Web of Science ®Google Scholar
• Henson D., Siegel S. E., Fucillo D. A., et al. Cytomegalovirus infections during acute childhood leukemia. J. Infect. Dis. 1972; 126: 469
   PubMed Web of Science ®Google Scholar
• Vaughan W. P., Saral R., Anderson L. R., Burke P. J. The frequency and pattern of cytomegalovirus (CMV) infection and shedding by patients who have received high dose times-sequential chemotherapy (TSC) for acute myelocytic leukemia (AML). Proc. 17th Annual Meeting Am. Soc. Clin. Oncol. 1981, 170, Abstract No. 673
   Google Scholar
• Wade J. C., Bustamante C. I., Newman K. A., Devlin A. M. Cytomegalovirus: an important pathogen for adults receiving induction therapy for acute leukemia. 28th Annual Intersci. Conf. on Antimicrobial Agents and Chemotherapy. 1988, Abstract No. 1394
   Google Scholar
• Wingard J. R., Chen D.H., Bums W. H., et al. Autologous Bone Marrow Transplantation: Comparison to Infection After Allogeneic Bone Marrow Transplantation. Blood 1988; 71: 1432–1437
   PubMed Web of Science ®Google Scholar
• Reusser P., Fisher L. D., Buckner C. D., Thomas E. D., Meyers J. D. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75: 1888–1894
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Meyers J. D., Fefer A., et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation 1982; 46: 61–65
   Google Scholar
• Miller W., Flynn P., McCullough J., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood 1986; 67: 1162–1167
   PubMed Web of Science ®Google Scholar
• Weiner R. S., Bortin M. M., Gale R. P., et al. Interstitial pneumonitis after bone marrow transplantation. Ann. Intern. Med. 1986; 104: 168–175
   PubMed Web of Science ®Google Scholar
• Wingard J. R., Mellits E. D., et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine (Baltimore) 1988; 67: 175–186
   PubMed Web of Science ®Google Scholar
• Wade J. C., Hintz M., McGuffin R. W., et al. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am. J. Med. 1982; 73A: 249
   Web of Science ®Google Scholar
• Shepp D. H., Dandliker P. S., de Miranda P., et al. Activity of 9– [2–hydroxy-l -(hydroxymethyl)ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann. Intern. Med. 1985; 103: 368
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Flournoy N., Sanders J. E., et al. Prophylactic human leukocyte interferon after allogeneic marrow transplantation. Ann. Intern. Med. 1987; 107: 809
   PubMed Web of Science ®Google Scholar
• Reed E. C., Bowden R. A., Dandliker P. S., et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J. Infect. Dis. 1987; 156: 641
   PubMed Web of Science ®Google Scholar
• Reed E. C., Bowden R. A., Dandliker P. S., et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern: Med. 1988; 109: 783–788
   PubMed Web of Science ®Google Scholar
• Emanuel D., Cunningham I., Jules-Elysee K., et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann. Intern. Med. 1988; 109: 777–782
   PubMed Web of Science ®Google Scholar
• Schmidt G. M., Kovacs A., Zaia J. A., et al. Ganciclovir/Immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988; 46: 905–907
   PubMed Web of Science ®Google Scholar
• Bratanow N. C., Ash R. C., Turner P. A. SUCcessful treatment of serious cytomegalovirus (CMV) disease with 9(1,3–dihydroxy-2–propoxymethyl)guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients. Exp. Hematol. 1987; 15: 541, Abstract No. 254
   Web of Science ®Google Scholar
• Grundy J. E., Shanley J. D., Griffiths P. D. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition. Lancet 1987; 2: 996
   PubMed Web of Science ®Google Scholar
• Aschan J., Ringden O., Ljungman P., Lönnqvist B., Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand. J. Infect. Dis. 1992; 24: 143–150
   PubMed Web of Science ®Google Scholar
• Reed E. C., Wolford J. L., Kopecky K. J., et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann. Intern. Med. 1990; 112: 505–510
   PubMed Web of Science ®Google Scholar
• Winston D. J., Ho W. G., Lin C.H., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 1987; 106: 12–18
   PubMed Web of Science ®Google Scholar
• Bowden R. A., Fisher L. D., Rogers K., Cays M., Meyers J. D. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J. Infect. Dis. 1991; 164: 483–487
   PubMed Web of Science ®Google Scholar
• Bowden R. A., Sayers M., Flournoy N., et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 1986; 314: 1006–1010
   PubMed Web of Science ®Google Scholar
• Winston D. J., Pollard R. B., Ho W. G., et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann. Intern. Med. 1982; 97: 11–18
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Leszcynski J., Zaia J. A., et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann. Intern. Med. 1983; 98: 442–446
   PubMed Web of Science ®Google Scholar
• O'Reilly R. J., Reich L., Gold J., et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: preliminary results. Transplant. Proc. 1983; 15: 1405–1411
   Web of Science ®Google Scholar
• Kubanek B., Ernest P., Ostendorf P., Schafer U., Woft H. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant. Prog. 1985; 17: 468–469
   Web of Science ®Google Scholar
• Winston D. J., Ho W. G., Lin C. H., et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 1987; 106: 12–18
   PubMed Web of Science ®Google Scholar
• Ringden O., Pihlstedt P., Volin L., et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987; 2: 299–305
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Kopecky K. J., Jocum J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 1990; 323: 105–712
   Google Scholar
• Bass E. B., Powe N. R., Graziano S. L., et al. Efficacy of Intravenous Immune Globulin in Preventing Complications of Bone Marrow Transplantation: A Meta Analysis. Bone Marrow Transplant 1992, In Press
   Web of Science ®Google Scholar
• Winston D. J., Ho W. G., Gale R. P., Champlin R. E. Treatment and prevention of interstitial pneumonia after bone marrow transplantation. Progress in bone marrow transplantation, R. P. Gale, R. E. Champlin. Alan R. Liss, New York 1987; 525–544
   Google Scholar
• Miller W., McCullough J., Balfour H. H., et al. Prevention of CMV infection by blood products: a randomized trial (abstract # K128). J. Cell. Biochem. 1988; 12(Suppl. C)93
   Google Scholar
• Bowden R. A., Sayers M., Slichter S. J., et al. Use of leukocyte-poor transfusions to prevent CMV infection after marrow transplant. Proceedings of the 2nd International CMV Workshop, San Diego, CA, 1989
   Google Scholar
• Meyers J. D., Reed E. C., Shepp D. H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Engl. J. Med. 1988; 318: 70
   PubMed Web of Science ®Google Scholar
• Schmidt G. M., Horak D. A., Niland J. C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N. Engl. J. Med. 1991; 324: 1005–1011
   PubMed Web of Science ®Google Scholar
• Goodrich J. M., Mori M., Cleaves C. A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N. Engl. J. Med. 1991; 325: 1601–1607
   PubMed Web of Science ®Google Scholar
• Goodrich J. M., Bowden R. A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann. Intern. Med. 1993; 118: 173–178
   PubMed Web of Science ®Google Scholar
• Winston D. J., Ho W. G., Bartoni K., et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. 1993; 118: 179–184
   PubMed Web of Science ®Google Scholar
• Atkinson K., Downs K., Golenia M., et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br. J. Haematol. 1991; 79: 57–52
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Ljungman P., Fisher L. D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J. Infect. Dis. 1990; 162: 373–380
   PubMed Web of Science ®Google Scholar
• Cleaves C. A., Smith T. F., Shuster E. A., Pearson G. R. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J. Clin. Microbiol. 1985; 21: 217
   PubMed Web of Science ®Google Scholar
• Crawford S. W., Bowden R. A., Hackman R. C., et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann. Intern. Med. 1988; 108: 180–185
   PubMed Web of Science ®Google Scholar
• Spector S. A., Memll R., Wolf D., et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J. Clin. Microbiol. 1992; 30: 2359–2365
   PubMed Web of Science ®Google Scholar
• Brytting M., Xu W., Wahren B., et al. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J. Clin. Microbiol. 1992; 30: 1937–1941
   PubMed Web of Science ®Google Scholar
• Wolf D., Spector S. A. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, 1992, 317, Abstract #1241
   Google Scholar
• Vlieger A. M., Boland G. J., Jiwa N. M., et al. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients. Bone Marrow Transplant 1992; 9: 247–253
   PubMed Web of Science ®Google Scholar
• van der Bij W., Torensma R., van Son W. J., et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J. Med. Virol. 1988; 25: 179–188
   PubMed Web of Science ®Google Scholar
• Jiwa N. M., van de Rijke F. M., Mulder A., et al. An improved immunocytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry 1989; 91: 345–349
   PubMedGoogle Scholar
• Boeckh M., Boweden R. A., Goodrich J. M., et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992; 80: 1358–1364
   PubMed Web of Science ®Google Scholar
• Buller R. S., Bailey T. C., Ettinger N. A. Use of a modified shell vial technique to quantitate cytomegalovirus viremia in a population of solid-organ transplant recipients. J. Clin. Microbiol. 1992; 30: 2620–2624
   PubMed Web of Science ®Google Scholar
• Locksley P. R. M., Flournoy N., Sullivan K. M., Meyers J. D. Infection with varicella-zoster virus after marrow transplantation. J. Infect. Dis. 1985; 152: 1172–1181
   PubMed Web of Science ®Google Scholar
• Schiller G. J., Nimer S. D., Gajewski J. L., Golde D. W. Abdominal presentation of varicella-zoster infection in recipients of allogenic bone marrow transplantation. Bone Marrow Transplant 1991; 7: 489–491
   PubMed Web of Science ®Google Scholar
• Atkinson K., Meyers J. D., Storb R., Prentice R. L., Thomas E. D. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47
   PubMed Web of Science ®Google Scholar
• Atkinson K., Farewell V., Storb R., et al. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982; 60: 714
   PubMed Web of Science ®Google Scholar
• Schuchter L. M., Wingard J. R., Piantadosi S., Bums W. H., Santos G. W., Saral R. Herpes Zoster Infection After Autologous Bone Marrow Transplantation. Blood 1989; 74: 1424–1427
   PubMed Web of Science ®Google Scholar
• Balfour H. H., Jr., Bean B., Laskin O. L., , the Burroughs Wellcome Collaborative Acyclovir Study Group, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N. Engl. J. Med. 1983; 308: 1448–1453
   PubMed Web of Science ®Google Scholar
• Meyers J. D., Wade J. C., Shepp D. H., Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984; 37: 571
   PubMed Web of Science ®Google Scholar
• Serota F. T., Starr S. E., Bryan C. K., et al. Acyclovir treatment of herpes zoster infections, use in children undergoing bone marrow transplantation. J. Am. Med. Assoc. 1982; 247: 2132–2135
   PubMed Web of Science ®Google Scholar
• Ljungman P., Lönnqvist B., Ringdén O., Skinhöj P., Gahrton G., for the Nordic bone Marrow Transplant Group. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 613–615
   PubMed Web of Science ®Google Scholar
• Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N. Engl. J. Med. 1986; 314: 208–212
   PubMed Web of Science ®Google Scholar
• Zaia J. A., Levin M. J., Preblud S. R., et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J. Infect. Dis. 1983; 147: 737
   PubMed Web of Science ®Google Scholar
• Gershon A. A. Live attenuated varicella vaccine: perspective. J. Infect. Dis. 1985; 152: 859
   PubMed Web of Science ®Google Scholar
• Gershon A. A. Live attenuated varicella vaccine. J. Pediatr. 1987; 110: 154
   PubMed Web of Science ®Google Scholar
• Gershon A. A., Steinberg S. P., The Varicella Vaccine Collaborative Study Group of the NIAID. Persistence of immunity of varicella in children with leukemia immunized with live attenuated varicella vaccine. N. Engl. J. Med. 1989; 320: 892
   PubMed Web of Science ®Google Scholar
• Gershon A. A., Steinberg S. P., the National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. J. Infect. Dis. 1990; 161: 661
   PubMed Web of Science ®Google Scholar
• Lawrence R., Gershon A. A., Holzman R., et al. The risk of zoster after varicella vaccination in children with leukemia. N. Engl. J. Med. 1988; 318: 543
   PubMed Web of Science ®Google Scholar
• Diaz P. S., Au D., Smith S., et al. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991; 87: 166–170
   PubMed Web of Science ®Google Scholar
• Ljungman P., Lönnqvist B., Gahrton G., et al. Clinical and subclinical reactivations with varicella-zoster virus in immunocompromised patients. J. Infect. Dis. 1986; 153: 840–844
   PubMed Web of Science ®Google Scholar
• Ljungman P., Wilczek H., Gahrton G., et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in-vitro. Bone Marrow Transplant 1986; 1: 185–192
   PubMed Web of Science ®Google Scholar
• Perren T. J., Powles R. L., Easton D., et al. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am. J. Med. 1988; 85: 99–101
   PubMed Web of Science ®Google Scholar
• Sempere A., Sanz G. F., Senent L., et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495–498
   PubMed Web of Science ®Google Scholar
• Shanley J. D., Pesanti E. L., Nugent K. M. The pathogenesis of pneumonitis due to murine cytomegalovirus. J. Infect. Dis. 1982; 146: 388–96
   PubMed Web of Science ®Google Scholar
• Shanley J. D., Pomeroy C., Via C. S., Shearer G. M. Interstitial pneumonitis during murine cytomegalovirus infection and graft-versus-host reaction: effect of ganciclovir therapy. J. Infect. Dis. 1988; 158: 1391–1394
   PubMed Web of Science ®Google Scholar
• Shanley J. D., Pesanti E. L. The relation of viral replication to interstitial pneumonitis in murine cytomegalovirus lung infection. J. Infect. Dis. 1985; 151: 454–458
   PubMed Web of Science ®Google Scholar
• Shanley J. D. Murine cytomegalovirus pneumonitis in T cell deficient nude mice. Abstracts of the 12th Herpesvirus Workshop. 1987
   Google Scholar
• Grundy J. E., Shanley J. D., Shearer G. M. Augmentation of graft versus host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation 1985; 39: 548–553
   PubMed Web of Science ®Google Scholar
• Quinnan G. V., Jr., Kirmani N., Rook A. H., et al. HLA-restricted T lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N. Engl. J. Med. 1982; 307: 7–13
   PubMed Web of Science ®Google Scholar
• Quinnan G. V., Jr., Bums W. H., Kirmani N., et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev. Infect. Dis. 1984; 6: 156–163
   PubMedGoogle Scholar
• Greenberg P. D., Reusser P., Goodrich J. M., et al. Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplant recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann. NY Acad. Sci. 1991; 636: 184–195
   PubMed Web of Science ®Google Scholar
• Tricot G., De Clercq M. A., Boogaerts M. A., Verwilghen R. L. Oral Bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J. Med. Virol. 1986; 18: 11–20
   PubMed Web of Science ®Google Scholar
• Machida H., Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol. Immunol. 1990; 34: 407–411
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B., Donnelly H., Groshen S., et al. 2–Fluro-5–Iodo-arabinosylcytosine, a new potent antiviral agent: efficacy in immunosuppressed individuals with herpes zoster. J. Infect. Dis. 1986; 154: 430–436
   PubMed Web of Science ®Google Scholar